Cargando…

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer

PURPOSE: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the...

Descripción completa

Detalles Bibliográficos
Autores principales: Marisa, Laetitia, Blum, Yuna, Taieb, Julien, Ayadi, Mira, Pilati, Camilla, Le Malicot, Karine, Lepage, Côme, Salazar, Ramon, Aust, Daniela, Duval, Alex, Blons, Hélène, Taly, Valérie, Gentien, David, Rapinat, Audrey, Selves, Janick, Mouillet-Richard, Sophie, Boige, Valérie, Emile, Jean-François, de Reyniès, Aurélien, Laurent-Puig, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974433/
https://www.ncbi.nlm.nih.gov/pubmed/34168047
http://dx.doi.org/10.1158/1078-0432.CCR-21-0529
_version_ 1784680238188331008
author Marisa, Laetitia
Blum, Yuna
Taieb, Julien
Ayadi, Mira
Pilati, Camilla
Le Malicot, Karine
Lepage, Côme
Salazar, Ramon
Aust, Daniela
Duval, Alex
Blons, Hélène
Taly, Valérie
Gentien, David
Rapinat, Audrey
Selves, Janick
Mouillet-Richard, Sophie
Boige, Valérie
Emile, Jean-François
de Reyniès, Aurélien
Laurent-Puig, Pierre
author_facet Marisa, Laetitia
Blum, Yuna
Taieb, Julien
Ayadi, Mira
Pilati, Camilla
Le Malicot, Karine
Lepage, Côme
Salazar, Ramon
Aust, Daniela
Duval, Alex
Blons, Hélène
Taly, Valérie
Gentien, David
Rapinat, Audrey
Selves, Janick
Mouillet-Richard, Sophie
Boige, Valérie
Emile, Jean-François
de Reyniès, Aurélien
Laurent-Puig, Pierre
author_sort Marisa, Laetitia
collection PubMed
description PURPOSE: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications. EXPERIMENTAL DESIGN: We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%. RESULTS: Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12–1.59), 1.40, 95% CI (1.14–1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells. CONCLUSIONS: This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine.
format Online
Article
Text
id pubmed-8974433
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-89744332023-01-05 Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer Marisa, Laetitia Blum, Yuna Taieb, Julien Ayadi, Mira Pilati, Camilla Le Malicot, Karine Lepage, Côme Salazar, Ramon Aust, Daniela Duval, Alex Blons, Hélène Taly, Valérie Gentien, David Rapinat, Audrey Selves, Janick Mouillet-Richard, Sophie Boige, Valérie Emile, Jean-François de Reyniès, Aurélien Laurent-Puig, Pierre Clin Cancer Res Precision Medicine and Imaging PURPOSE: The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications. EXPERIMENTAL DESIGN: We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%. RESULTS: Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12–1.59), 1.40, 95% CI (1.14–1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells. CONCLUSIONS: This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine. American Association for Cancer Research 2021-06-24 /pmc/articles/PMC8974433/ /pubmed/34168047 http://dx.doi.org/10.1158/1078-0432.CCR-21-0529 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.
spellingShingle Precision Medicine and Imaging
Marisa, Laetitia
Blum, Yuna
Taieb, Julien
Ayadi, Mira
Pilati, Camilla
Le Malicot, Karine
Lepage, Côme
Salazar, Ramon
Aust, Daniela
Duval, Alex
Blons, Hélène
Taly, Valérie
Gentien, David
Rapinat, Audrey
Selves, Janick
Mouillet-Richard, Sophie
Boige, Valérie
Emile, Jean-François
de Reyniès, Aurélien
Laurent-Puig, Pierre
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
title Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
title_full Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
title_fullStr Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
title_full_unstemmed Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
title_short Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
title_sort intratumor cms heterogeneity impacts patient prognosis in localized colon cancer
topic Precision Medicine and Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974433/
https://www.ncbi.nlm.nih.gov/pubmed/34168047
http://dx.doi.org/10.1158/1078-0432.CCR-21-0529
work_keys_str_mv AT marisalaetitia intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT blumyuna intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT taiebjulien intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT ayadimira intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT pilaticamilla intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT lemalicotkarine intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT lepagecome intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT salazarramon intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT austdaniela intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT duvalalex intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT blonshelene intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT talyvalerie intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT gentiendavid intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT rapinataudrey intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT selvesjanick intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT mouilletrichardsophie intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT boigevalerie intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT emilejeanfrancois intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT dereyniesaurelien intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer
AT laurentpuigpierre intratumorcmsheterogeneityimpactspatientprognosisinlocalizedcoloncancer